Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Daiichi Sankyo
QuintilesIMS
Cantor Fitzgerald
Citi
Baxter
AstraZeneca
Accenture
Federal Trade Commission

Generated: June 25, 2018

DrugPatentWatch Database Preview

ALREX Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Alrex, and when can generic versions of Alrex launch?

Alrex is a drug marketed by Bausch And Lomb and is included in one NDA.

The generic ingredient in ALREX is loteprednol etabonate. There are ten drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
Drug patent expirations by year for ALREX
Pharmacology for ALREX
Medical Subject Heading (MeSH) Categories for ALREX
Synonyms for ALREX
(non-labelled)Loteprednol Etabonate-d5
034L466
17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylic acid chloromethyl ester
82034-46-6
A840238
AB0014233
AB00698349_08
AB00698349-05
AB00698349-07
AB2000207
AC-3403
AC1L1HRL
AC1L9FKJ
AJ-113709
AK128804
AKOS005145741
AKOS015969680
AKOS016842709
AKOS025402030
AKOS026749817
Alrex, Lotemax, Loteprednol etabonate
Alrex;Lotemax
AN-5197
Androsta-1,4-diene-17-carboxylic acid, 17-((ethoxycarbonyl)oxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11beta,17alpha)-
BC208448
Bio-0130
C24H31ClO7
CAS-82034-46-6
CCG-101041
CDDD 5604
CDDD-5604
CEHOAC
CHEBI:31784
CHEMBL1200865
chloromethyl (10R,11S,13S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
chloromethyl (1S,2R,10S,11S,14R,15S,17S)-14-[(ethoxycarbonyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-14-carboxylate
chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-((ethoxycarbonyl)oxy)-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carb
chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
chloromethyl (8S,9S,10R,11S,13S,14S,17S)-17-((ethoxycarbonyl)oxy)-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylate
Chloromethyl 11beta,17-dihydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate, 17-(ethyl carbonate)
CHLOROMETHYL 14-[(ETHOXYCARBONYL)OXY]-17-HYDROXY-2,15-DIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIENE-14-CARBOXYLATE
chloromethyl 17-ethoxycarbonyloxy-10,13-dimethyl-11-oxidanyl-3-oxidanylidene-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate
chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate
CPD000469178
CS-0900
CTK8G0640
D01689
D0X6GN
DMKSVUSAATWOCU-HROMYWEYSA-N
DR002901
DSSTox_CID_26468
DSSTox_GSID_46468
DSSTox_RID_81641
DTXSID2046468
GS-3599
GTPL7085
HGP 1
HGP-1
HMS2051F16
HMS2232J09
HMS3372I17
HMS3393F16
HMS3655K17
HY-17358
I06-0442
IDR-90102
IDR-90103
Inveltys
K462
KS-00000GI4
Locort
Loteflam
Lotemax
Lotemax (TN)
Loteprednol etabonate
Loteprednol etabonate (JAN/USAN)
Loteprednol etabonate [USAN:JAN]
Loteprednol etabonate [USAN]
Loteprednol etabonate Opphthalmic suspension
Loteprednol Etabonate, >=98% (HPLC)
Loterox
LS-177664
M-9411
MCULE-5760267673
MFCD00870765
MLS001424221
MolPort-003-848-424
MolPort-005-980-183
MolPort-006-830-025
MolPort-027-948-426
NC00291
NCGC00164594-01
NCGC00164594-02
P 5604
P-5604
PL070795
s1669
SAM001246630
SCHEMBL12045348
SCHEMBL12738239
SCHEMBL13379816
SCHEMBL23907
SCHEMBL506024
SMR000469178
ST24030829
Tox21_112219
Tox21_112219_1
UNII-YEH1EZ96K6
YEH1EZ96K6
ZINC3920673
ZINC59803238

US Patents and Regulatory Information for ALREX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb ALREX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020803-001 Mar 9, 1998 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ALREX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb ALREX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020803-001 Mar 9, 1998 ➤ Sign Up ➤ Sign Up
Bausch And Lomb ALREX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020803-001 Mar 9, 1998 ➤ Sign Up ➤ Sign Up
Bausch And Lomb ALREX loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 020803-001 Mar 9, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
US Army
Boehringer Ingelheim
Mallinckrodt
McKinsey
Baxter
Medtronic
Moodys
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.